Ixico (IXI.L) Maintains Flat Performance Amid Market Volatility

Ixico plc (IXI.L) closed unchanged at 0 % during a 24‑hour trading window that concluded at 01:42 AM Central Europe on Saturday, 24 th. The share price currently trades at roughly GBX 10 on the most liquid exchanges, reflecting a modest upside of 13.33 % since the close of last month.

With a market capitalisation of GBX 32.2 million and an outstanding supply of 219 million shares, Ixico’s trading volume over the past day was approximately GBX 176.9 k. The 200‑day simple moving average sits at GBX 8.28, positioning the stock above its medium‑term trend line. The highest point reached in the preceding 52 weeks was GBX 13 on 12 October 2025, while the trough of the same period fell to GBX 6.26 on 13 May 2026.

Peer Comparison

  • Kendrick (KEN.L) – Down 2.86 %, now at GBX 4; market cap GBX 37.2 million.
  • Lords Trading (LORD.L) – Flat; trading at GBX 12.5; market cap GBX 34.5 million.
  • Krm (KRM.L) – Flat; trading at GBX 34.5; market cap GBX 35.4 million.
  • Provexis (PXS.L) – Flat; trading at GBX 0.95; market cap GBX 36.5 million.
  • Earnz (EARN.L) – Flat; trading at GBX 5.12; market cap GBX 37.2 million.

Ixico’s contemporaneous peers exhibit a mixed performance profile, with Kendrick’s modest decline contrasting the flat readings across Lords Trading, Krm, Provexis, and Earnz. This stability suggests that Ixico’s valuation is resilient to short‑term market swings, a factor that will be of particular interest to investors monitoring the health‑tech sector.

Company Snapshot

Ixico plc, headquartered in London, is a provider of technology solutions tailored to the research, diagnosis, and treatment of serious diseases—especially neuro‑degenerative disorders. Its proprietary platforms, TrialWire™ and TrialTracker™, have supported clinical trials for Alzheimer’s therapies and are integral to the company’s product suite. The firm remains listed on the London Stock Exchange and maintains an active online presence at www.ixico.com . Ixico completed its initial public offering on 25 April 1996.

This report reflects current market data and the company’s publicly disclosed information. It is intended for informational purposes and does not constitute investment advice.